  Burosumab-twza ( Crysvita) for a rare inherited form of rickets; ibalizumab-uiyk ( Trogarzo) for human<pathogen> immunodeficiency<pathogen> virus<pathogen> type 1 infection; and tildrakizumab-asmn ( Ilumya) for adults with moderate-to-severe plaque psoriasis.